Frequently Asked Questions

Mounjaro® contains tirzepatide but is primarily used for type 2 diabetes. Zepbound® contains the same active ingredient and is approved for weight management in eligible adults.

Results vary depending on dosage, starting weight, lifestyle and treatment consistency. No specific amount of weight loss can be guaranteed.

Some clients notice reduced hunger and cravings within the first few weeks. Weight loss usually develops gradually as the dosage is increased and healthier habits are established.

Weight regain can occur if appetite returns after medication is discontinued. Your provider will help create an appropriate long-term maintenance plan based on your progress and health needs.

Treatment may not be suitable during pregnancy or for clients with certain medical conditions, including a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. A full medical assessment is required before treatment.

No. Compounded medications are not FDA-approved and have not undergone the same review for safety, quality and effectiveness as approved products. Your provider should clearly explain which medication is being prescribed.